Date: 2015-12-02
Type of information: Nomination
Compound:
Company: Affimed (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 2, 2015, Affimed, a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, announced that Andrew Curtis has joined Affimed as Head of Corporate Strategy and Business Development. He brings more than two decades of expertise from large pharmaceutical companies, most notably Pfizer, and as a biotechnology entrepreneur. Andrew has spent more than twenty years in the pharmaceutical and biotechnology sectors, focusing on the licensing, commercial development and commercialization of new medicines for rare and neglected diseases. Since leaving Pfizer in 2014, Andrew has been involved in entrepreneurial and advisory activities. At Pfizer, Andrew led the Specialty Care Business Unit\'s External Opportunities and New Business team as well as Pfizer\'s BioTherapeutic\'s Business Innovation and Strategy team, focusing on novel Open Innovation models in support of the BioTherapeutics R&D organization. Previously, Andrew was Global Team Lead for the Biosimilars and Orphan Drugs division within Pfizer\'s Established Products Business Unit, where he crafted the company\'s first-ever rare disease unit and biosimilar program strategies. Prior to rejoining Pfizer in 2008, Andrew was CEO of Jerini US Inc., a company focused on the development and commercialization of icatibant, a treatment for hereditary angioedema, subsequently commercialized under the brand name Firazyr by Shire after it acquired Jerini in 2008. His career also includes commercial marketing and sales positions with Pfizer, Genzyme, TargetRx, J&J, and Merck. Andrew holds a B.A. from Muhlenberg College and a M.A. from Lehigh University.
Financial terms:
Latest news:
